Search
Acute rheumatic fever and rheumatic heart disease disproportionately affect Aboriginal and Torres Strait Islander people in Australia, with devastating impacts on morbidity, mortality and community wellbeing. Research suggests that general practitioners and primary care staff perceive insurmountable barriers to improving clinical outcomes, including the need for systemic change outside their scope of practice.
Regular intramuscular benzathine penicillin G injections have been the cornerstone of rheumatic heart disease (RHD) secondary prophylaxis since the 1950s. As the pharmacological correlate of protection remains unknown, it is difficult to recommend changes to this established regimen. Determining the minimum effective penicillin exposure required to prevent Streptococcus pyogenes infection will accelerate development of new long-acting penicillins for RHD prevention as well as inform opportunities to improve existing regimens. The CHIPS trial will address this knowledge gap by directly testing protection afforded by different steady state plasma concentrations of penicillin in an established model of experimental human S. pyogenes pharyngitis.
Group A Streptococcus (Strep A) is responsible for a significant global health and economic burden. The recent prioritization of Strep A vaccine development by the World Health Organization has prompted global research activities and collaborations. To progress this prioritization, establishment of robust surveillance for Strep A to generate updated regional disease burden estimates and to establish platforms for future impact evaluation is essential.
The search for clinically effective antivirals against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is ongoing. Repurposing of drugs licensed for non–coronavirus disease 2019 (COVID-19) indications has been extensively investigated in laboratory models and in clinical studies with mixed results.
A new report predicts rheumatic heart disease (RHD) will lead to over 500 preventable deaths and cost the Australian health system $317 million by 2031 if no further action to tackle the disease is taken.
The END RHD CRE is producing a costed, step-wise strategy to end rheumatic heart disease (RHD) as public health priority in Australia.
Rheumatic heart disease, a deadly yet entirely preventable heart disease taking the lives of Aboriginal and Torres Strait Islander people, is finally on the verge of elimination thanks to new research
Collaboration is the driving force behind ‘END RHD Demonstration Communities’ – a new community-driven, research-backed approach to tackling rheumatic heart disease (RHD) in remote Australia.
Between 3rd - 5th May 2018, researchers from Australia, New Zealand, South Africa, and the United States (representing their Uganda collaboration) convened in Fremantle, Western Australia to attend the Strep A Spectrum Meetings: from Science to Strategy.
The Kids Research Institute Australia & Menzies School of Health Research will lead an international project to develop a diagnostic tool for acute rheumatic fever.